Outlook Therapeutics Gains as FDA Timeline for Lytenava Comes Up
Outlook Therapeutics shares surged Wednesday as the stock once again drew regulatory-timer trades after the company filed its newest FDA application for ONS-5010/LYTENAVA, its candidate for wet age-related macular degeneration. The stock was last quoted near $0.89, up about 26% from Tuesday's close, with shares trading between $0.6853 and $0.8999 and volume near 21.9 million shares. Investors are focused on timing. Outlook said June 1 it resubmitted its Biologics License Application, or BLA, for ONS-5010/LYTENAVA to the FDA. The drug targets neovascular age-related macular degeneration, or wet AMD, which affects central vision.
